jdm

Journal of Diabetes & Metabolism

ISSN - 2155-6156

Abstract

Steatosis, Glycation and Liver Fibrosis in Patients with Diabetes

Marty M, Hiriart JB, Vergniol J, Foucher J, De Ledinghen V, Gin H, Rigalleau V

Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is frequent and progresses to fibrosis among patients with diabetes. The roles of hepatic steatosis and of the accumulation of Advanced Glycation Endproducts (AGEs) can now be analyzed by new non-invasive methods. Patients and methods: Among hospitalized patients with diabetes, we assessed liver fibrosis by liver stiffness measurement (LSM), steatosis by the attenuation coefficient of an ultrasonic wave (CAP) and AGE accumulation by skin autofluorescence (sAF). The patients with severe fibrosis were compared to the others by ANOVA and Chi-2, and the relations between fibrosis, steatosis, and skin AF were studied by regression analysis. Results: 178 patients were included: 60% male, age 59 ± 11 years, BMI 31 ± 6 kg/m2, 79% with Type 2 Diabetes (T2D), poorly controlled (HbA1C 9.0 ± 2.4%). sAF were available in all patients, LSM in 139 and CAP in 93 subjects. Severe fibrosis (LSM>8.7 kPa) was evidenced in 32 (23%) patients, mainly T2D (n=31/32), with higher BMI and waist circumference (p<0.0001). They had higher CAP: 319 ± 53 dB/m (No fibrosis: 268 ± 59, p<0.005), whereas their sAF did not differ. LSM was correlated to the CAP (r=0.40, p<0.0001) and the waist circumference (r=0.46, p<0.0001), but not to sAF. CAP was related to waist circumference and triglycerides level (r=0.70 in multivariate analysis). 1.4 Conclusion: More steatosis and similar skin autofluorescence in patients with diabetes and severe liver fibrosis support that steatosis promotes fibrosis, and suggests that AGEs do not accelerate this progression.

Top